Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”
International medical journal hosts review of contract plasma fractionation dynamics
Kedrion Biopharma strengthens its presence in Russia
Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program
FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin
Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017
Hemophilia seen through children’s eyes: Kedrion teams up with LA Kelley
Three books of the series My First Factor Creation are now available for free download
Kedrion took part in the 17th ESID Meeting with 44 international guests
The conference focused on new insights into PIDs’ diagnosis and therapies
Pharmaceutical digitization: how to improve patient care and engagement
Kedrion Biopharma Advisor Prof. Albert Farrugia lectures at “The Future of Science” Conference in Venice, Italy
Humanitarian Factor IX donation to Afghanistan
Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries
Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment
BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017
SIPPET Study was WHF 2016 World Congress highlight
A Kedrion, Grifols and LFB supported symposium featured a lecture by Dr. Manuel Carcao
Kedrion Biopharma consolidates presence on Russian market
Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant